Creative Touch Permanent Makeup and Aesthetics

Platelets are the biological mechanism behind PRP and iPRF, but understanding them only as “the things that release growth factors” undersells both what they are and why the preparation method matters so much. The alpha granule payload is a precisely coordinated cocktail of several hundred proteins that work synergistically, not independently. The difference between PRP and iPRF is not primarily a difference in which growth factors are present but a difference in how the fibrin matrix forms and how long it releases them. And the reason that difference matters is rooted in the platelet’s activation biology: how thrombin concentration during preparation determines whether fibrin polymerises fast or slow, and whether growth factors are trapped for sustained release or freed in a single early burst.

Platelets are the smallest formed element in blood. 2–4 µm in diameter, anucleate (they contain no nucleus and no DNA), and produced not by conventional cell division but by fragmentation of their precursor cells. ^[4] Megakaryocytes in the bone marrow extend long cytoplasmic projections called proplatelets into the bone marrow sinusoids, and circulating blood flow shears platelets from the proplatelet tips directly into circulation – an unusual production mechanism that reflects the fact that platelets are functional fragments rather than complete cells. rupress.org Approximately 10¹¹ platelets are produced this way every day, each surviving in circulation for seven to ten days before clearance. ^[4]

Two Granule Types: Different Roles, Coordinated Release

Platelets contain two functionally distinct granule populations that are released in a coordinated sequence during activation, each with a different biological role.

Alpha granules are the larger and more numerous of the two, and contain several hundred proteins, the largest of which is the growth factor and structural protein payload that makes platelets relevant to regenerative medicine. ^[1] The growth factor contents include all three PDGF isoforms (PDGFaa, PDGFbb, PDGFab), TGF-β1 and TGF-β2, VEGF, EGF, IGF-1, FGF, and hepatocyte growth factor (HGF). ^[5] Alongside these, alpha granules contain the structural and haemostatic proteins fibrinogen, von Willebrand factor, fibronectin, thrombospondin, and platelet factor 4 – the proteins that form the physical scaffold of the clot and the fibrin matrix. ^[1]

Dense granules are smaller, fewer, and contain a distinct set of small molecules: ADP, ATP, serotonin, calcium, polyphosphate, and serotonin. ^[2] Their function is primarily amplification. When released, ADP and serotonin act as autocrine and paracrine agonists that recruit additional circulating platelets to the activation site, accelerating and amplifying the haemostatic response. ^[2] Dense granule calcium contributes to the intracellular signalling cascade within the activating platelet itself. In regenerative treatments, the dense granule contents are less directly relevant than the alpha granule payload, but the amplification cascade they drive is what ensures full platelet activation and complete alpha granule exocytosis occurs at the treatment site.

Platelet Activation: The Cascade

Resting platelets circulate in a discoid, non-adhesive state. Activation is triggered by contact with primary agonists – most relevantly, collagen exposed at sites of vascular or tissue injury (via the GPVI receptor) and thrombin generated by the coagulation cascade (via PAR receptors). nature.com These primary agonists trigger integrin αIIbβ3 activation (shape change, adhesion, and aggregation) and the release of ADP and thromboxane A₂ from dense granules as secondary amplifiers. jci.org ADP acts through P2Y1 and P2Y12 receptors on neighbouring platelets, triggering calcium influx and perpetuating the activation cascade outward through the platelet aggregate. Alpha granule exocytosis – the release of growth factors, fibrinogen, and structural proteins – occurs as part of this full activation response. ashpublications.org

Thrombin, the coagulation protease generated in the cascade, also converts plasma fibrinogen to fibrin – the structural protein that polymerises into a mesh, entrapping activated platelets, growth factors, and plasma proteins into the clot or, in iPRF, the fibrin matrix. The concentration of thrombin at which this polymerisation occurs is the variable that most directly distinguishes PRP from iPRF in terms of therapeutic behaviour.

Alpha Granule Growth Factor Synergy

The growth factors within platelet alpha granules do not act independently – they interact, and the balance of the full payload matters more than any individual component. At submaximally effective concentrations, PDGF, EGF, and IGF-1 show additive effects on cell proliferation. ^[3] TGF-β in the same payload is concentration-dependent in its behaviour – stimulatory at low concentrations and inhibitory at higher ones – meaning that the ratio of TGF-β to the proliferative growth factors in the released payload determines whether the net cellular response is one of proliferation, differentiation, or inhibition. ^[3] This is precisely why preparations that isolate or concentrate individual growth factors do not replicate the clinical effect of the whole platelet payload. The synergy is an intrinsic property of the cocktail, not achievable by summing its components separately.

Why the Fibrin Matrix Determines Release Duration

When platelets activate and alpha granule contents are released, fibrinogen from the same granules is simultaneously converted to fibrin by thrombin. The architecture of the fibrin network that forms depends critically on how much thrombin is present during polymerisation.

At high thrombin concentrations, as occurs when exogenous thrombin or calcium chloride is added to activate PRP, fibrin polymerises rapidly, forming a tight network. ^[6] Growth factors released into this environment are largely trapped in colloidal suspension between the fibrin strands and released massively within the first hour of the clot forming. The acute growth factor pulse is significant, but brief.

At low thrombin concentrations – as occurs in iPRF, where blood is collected without anticoagulant into glass tubes that slowly activate the contact pathway, generating thrombin endogenously at low levels – fibrin polymerises slowly, forming an equilateral-junction flexible network rather than a tight mesh. ^[6] This slow polymerisation allows substantially greater entrapment of circulating cytokines and growth factors within the fibrin architecture itself, held physically within the matrix rather than in suspension above it. These entrapped molecules are released only as the fibrin matrix undergoes natural remodelling over days to weeks – providing sustained growth factor delivery over seven to fourteen days rather than an acute burst. ^[6] iPRF specifically shows enhanced long-term release of PDGF-AA, PDGF-AB, EGF, and IGF-1 at ten days compared to standard PRP preparations. ^{[6] [7]}